Sagimet Biosciences (SGMT) Other Non-Current Liabilities (2022 - 2023)

Sagimet Biosciences' (SGMT) quarterly Other Non-Current Liabilities came in at $1000.0 in Q3 2023, down 80.0% quarter-over-quarter from $5000.0 in Q2 2023.

Sagimet Biosciences (SGMT) Other Non-Current Liabilities (2022 - 2023) Analysis & Trends

Sagimet Biosciences' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $1000.0 for Q3 2023.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $1000.0 in Q3 2023; TTM through Sep 2023 was $1000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $4000.0, changed N/A from the prior year.
  • Other Non-Current Liabilities fell to $1000.0 in Q3 2023 per SGMT's latest filing, from $5000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $5000.0 in Q2 2023 and bottomed at $1000.0 in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Sagimet Biosciences 227.27 Mn 227.27 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2023 1,000.00
Jun 30, 2023 5,000.00
Dec 31, 2022 4,000.00